100 Most Influential People in Healthcare - 2024

Dudum, who co-founded the company then known as Hims in 2017, has shepherded the organization through going public and expanding its direct-to-consumer offerings. In May, Hims & Hers joined the glucagon-like peptide-1 agonist (GLP-1) game by offering compounded versions of the weight-loss medication. A few months later, the company bought a sterile compounding facility in California. And in response to moves by the Food and Drug Administration to determine whether the active ingredient in some GLP-1 medications should be included on the agency’s shortage list — possibly affecting the legality of compounded GLP-1s — Hims & Hers launched a GLP-1 tracker in November with an eye toward letting the government know the drugs are hard to find. Dudum, who also serves on Hims & Hers’ board, previously co-founded Atomic Labs, a startup studio and investment fund.